Stockscreener 앱 받기
1.00
0.00%
0.00
시간 외 거래:
.98
-0.02
-2.00%
전일 마감가:
$1.00
열려 있는:
$1
하루 거래량:
296.77K
Relative Volume:
0.45
시가총액:
$15.08M
수익:
-
순이익/손실:
$-11.90M
주가수익비율:
-0.00485
EPS:
-206.0125
순현금흐름:
$-12.75M
1주 성능:
-7.41%
1개월 성능:
+21.07%
6개월 성능:
-4.76%
1년 성능:
+390.20%
1일 변동 폭
$0.9971
$1.04
1주일 범위
$0.9827
$1.10
52주 변동 폭
$0.1131
$3.95
Allarity Therapeutics Inc Stock (ALLR) Company Profile
명칭
Allarity Therapeutics Inc
전화
401-426-4664
주소
24 SCHOOL ST., 2ND FLOOR, BOSTON
ALLR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.00 | 16.29M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Allarity Therapeutics Inc 주식(ALLR)의 최신 뉴스
Allarity Therapeutics Secures New EU Commercial Agreement - TipRanks
Why Allarity Therapeutics Inc. stock attracts strong analyst attentionTop Rated Trade Entries - Newser
How Allarity Therapeutics Inc. stock performs during market volatilityHigh Potential Shares - Newser
What makes Allarity Therapeutics Inc. stock price move sharplyReal Time Stock Signal - Newser
Allarity Therapeutics Announces New Licensing and - GlobeNewswire
Allarity Therapeutics Signs New Precision Oncology Licensing Deal for Breast Cancer | ALLR Stock News - Stock Titan
Allarity Therapeutics appoints Jeff Ervin as CFO - MSN
Jeffrey S. Ervin Appointed as Allarity’s New CFO - The Globe and Mail
Allarity Therapeutics appoints Jeff Ervin as new CFO By Investing.com - Investing.com Nigeria
Allarity Therapeutics, Inc. Announces Chief Financial Officer Changes - MarketScreener
Allarity Therapeutics appoints Jeffrey S. Ervin as part-time chief financial officer - Investing.com Nigeria
Allarity Therapeutics appoints Jeff Ervin as new CFO - Investing.com
Allarity Therapeutics Appoints Jeff Ervin To Succeed Alexander Epshinsky As CFO - Nasdaq
Allarity Therapeutics Appoints Jeff Ervin as New Chief Financial Officer - Nasdaq
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer - GlobeNewswire
Former NYSE Executive Takes CFO Role at Cancer Drug Developer Allarity Therapeutics - Stock Titan
Allarity Therapeutics Secures Australian Patent for DRP® Platform - The Globe and Mail
Allarity Therapeutics Advances Phase 2 Stenoparib Trial - TipRanks
Allarity Therapeutics receives patent acceptance in Australia for cancer diagnostic - Investing.com
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic - The Manila Times
Allarity Therapeutics Doses Second Patient in Phase 2 Ovarian Cancer Trial - MarketScreener
Allarity Therapeutics Holds Annual Stockholders Meeting - TipRanks
Allarity Therapeutics Stock Nears Yearly Low: A Trader’s High-Risk Analysis - thekhabrilal
Allarity Therapeutics, Inc Announces Changes to Board of Directors - MarketScreener
Allarity Therapeutics appoints pharma veteran Høiland to board - Investing.com India
Allarity Therapeutics Appoints Jesper Høiland to Board - TipRanks
Allarity Therapeutics appoints pharma veteran Høiland to board By Investing.com - Investing.com Nigeria
Allarity Therapeutics Announces Changes To Board Of Directors - MarketScreener
Allarity Therapeutics Announces Changes to Board of Directors - GlobeNewswire
Pharma Veteran Jesper Høiland Brings 30 Years Experience to Allarity Board Amid Clinical Momentum - Stock Titan
Allarity Therapeutics (NASDAQ:ALLR) Shares Up 4.2% – Here’s Why - Defense World
Wolf Haldenstein Adler Freeman & Herz LLP Announces that it is Investigating Allarity Therapeutics, Inc. for Potential Violations of Federal Securities Laws - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation - ACCESS Newswire
Allarity Therapeutics Partners with Indiana Biosciences - TipRanks
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - Defense World
Allarity Therapeutics partners with IBRI on cancer drug research By Investing.com - Investing.com South Africa
Allarity Teams With IBRI To Advance Dual-Action Cancer Drug Stenoparib - Nasdaq
Allarity Therapeutics partners with IBRI on cancer drug research - Investing.com Australia
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Advance Understanding of Stenoparib's Mechanism of Action - Nasdaq
Allarity Therapeutics Announces Research Collaboration with - GlobeNewswire
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action - Yahoo
Allarity Therapeutics Launches Phase 2 Trial for Stenoparib - TipRanks
Allarity Therapeutics Announces First Patient Enrolled in - GlobeNewswire
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer - The Manila Times
Allarity Therapeutics Enrolls First Patient in Phase 2 Trial of Stenoparib for Advanced Ovarian Cancer - Nasdaq
Allarity Therapeutics Inc (ALLR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.37%
자본화:
|
볼륨(24시간):